The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

The Rock & Roll Hall of Fame was probably the furthest thing from the minds of Jack White and Meg White when they stepped into a gritty Cass Corridor bar to play their first gig for a handful of ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron Pharmaceuticals stock was among the ... writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with ...

Amazon on Tuesday denied a report that the e-commerce giant would soon display how much President Donald Trump’s tariffs will add to the cost of each item for sale on its site after the White ...

Regeneron Q1 EPS fell 14% to $8.22, missing estimates; revenue dropped 4% to $3.03 billion, also below consensus. Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss ...

The White House on Tuesday bashed Amazon for reportedly planning on displaying how much President Trump’s tariffs added to the cost of an item, calling it an aggressive move by the e-commerce giant.

Drinking white wine and Champagne, eating more fruit and keeping waistlines slim could reduce the risk of sudden cardiac arrest, according to a new study. Experts have suggested thousands of ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...